Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study
暂无分享,去创建一个
Steven Hawken | Salim Yusuf | Krisela Steyn | Xingyu Wang | S. Yusuf | S. Hawken | S. Ôunpuu | J. Sanderson | K. Kazmi | Xingyu Wang | M. McQueen | K. Steyn | John E Sanderson | Matthew J McQueen | A. Sniderman | Stephanie Ounpuu | Khawar Kazmi | Allan Sniderman | Jeffrey Probstfield | Mohammad Hasani | Emilia Volkova | J. Probstfield | E. Volkova | M. Hasani | Jeffrey Probstfield
[1] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[2] M. Pencina,et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. , 2007, JAMA.
[3] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[4] G. Walldius,et al. The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.
[5] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[6] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .
[7] Nader Rifai,et al. Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men , 2005, Circulation.
[8] K. Jablonski,et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. , 2003, Diabetes care.
[9] A. Zwinderman,et al. Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk , 2007, Annals of Internal Medicine.
[10] A. Sniderman,et al. Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort. , 2007, Clinical biochemistry.
[11] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[12] M. Blaser,et al. Population attributable risks of esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.
[13] F. Hu,et al. patient-oriented and epidemiological research Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese , 2007 .
[14] Curt D. Furberg,et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk , 2004, Clinical chemistry and laboratory medicine.
[15] A. Negassa,et al. INTER-HEART: A global study of risk factors for acute myocardial infarction. , 2001, American heart journal.
[16] R. McPherson,et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[17] J. Manson,et al. Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines , 2004, Circulation.
[18] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.
[19] R. Krauss,et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.
[20] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[21] Curt D. Furberg,et al. Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.
[22] S. Johansson,et al. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Göteborg, Sweden. , 1997, European heart journal.
[23] G. Dagenais,et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.
[24] D R Shapiro,et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.